With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 ...

The FDA has approved AstraZeneca's Tagrisso (osimertinib) to treat adults with unresectable stage III EGFR-mutated NSCLC.

The US FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.

UNICEF has reached an agreement with mpox vaccine manufacturer Bavarian Nordic to supply one million doses of the shot for ...

Safety processes and regulations apply to custom-made medicines, which differ from traditional pharmacies. Now, however, ...

The collaboration aims to utilise Tempus’ real-world data and biological modelling to enhance the development of Takeda’s ...

Phare Bio has received up to $27m from the Advanced Research Projects Agency for Health (ARPA-H) to advance its drug ...

Opioid use disorder (OUD) is a chronic neurological disorder characterised by the compulsive, repeated use of opioids, ...

Biocon has entered a partnership with Tabuk for the commercialisation of glucagon-like peptide-1 (GLP-1) products in the ...

Direct-to-patient communication is emerging as a powerful solution to the challenges of non-adherence to medication. By ...